Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.

TO THE EDITOR: The “unclassifiable” myelodysplastic/myeloproliferative neoplasms (MDS/MPN-U) remain the most poorly characterized among the various subtypes of MDS/MPN.[1][1] Retrospective studies have reported the median survival of patients with MDS/MPN-U to be 21 months from diagnosis[2][2]

[1]  A. Tefferi,et al.  Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management , 2018, American journal of hematology.

[2]  W. Hogan,et al.  Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience , 2018, Leukemia & lymphoma.

[3]  Z. Estrov,et al.  A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms , 2018, American journal of hematology.

[4]  J. Teruya-Feldstein,et al.  JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition , 2018, The Journal of clinical investigation.

[5]  Delong Liu,et al.  SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome , 2017, Biomarker Research.

[6]  Anthony Stein,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[7]  A. Tefferi,et al.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS‐T): 2017 update on diagnosis, risk‐stratification, and management , 2017, American journal of hematology.

[8]  J. Maciejewski,et al.  Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2016, Leukemia.

[9]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[10]  F. Stingo,et al.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. , 2014, Blood.

[11]  H. Kantarjian,et al.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.

[12]  H. Kantarjian,et al.  Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy , 2014, Leukemia.

[13]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[14]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[15]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[16]  C Haferlach,et al.  SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations , 2013, Leukemia.

[17]  D. Birnbaum,et al.  SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias , 2013, Leukemia.

[18]  Roberta Spinelli,et al.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia , 2012, Nature Genetics.

[19]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[20]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[22]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[23]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[24]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.